INVESTMENT TRENDS - A Rise in IPOs Revive Investments for the Global Pharma & Biotech Industry November 17, 2014

Dr. E. Saneesh, Financial Analyst at Frost & Sullivan, reports that new analysis reveals that PEVC investors in the global pharmaceutical and biotechnology industry have demonstrated maximum interest in oncology drugs, followed by anti-infective drugs and pharmaceutical contract laboratories. They also conclude the maximum pharmaceutical- and biotechnology-related PEVC deals in the US, and are expected to continue to do so in the forthcoming years.

SPECIAL ROUNDTABLE - Leadership Panel: 4 Trends That Will Have the Most Impact on Drug Development in 2024 January 26, 2024

Contributor Cindy H. Dubin asked some of today’s life science leaders what they expect will have the greatest impact on drug development in 2024 and beyond.

MARKET TRENDS - The Year of Resilience & Flexibility: Six Smart Ways CDMOs Are Preparing for 2023 April 3, 2023

Carsten Press says with biopharma businesses weathering one unexpected shift after another, it’s no surprise these organizations are looking to their partner networks for one thing above all: the flexibility they need to maximize their own business resilience.

MARKET TRENDS - Emerging Trends in Injectable Drug Formulation & Delivery March 1, 2023

Martin Gonzalez, PhD, details current trends in sterile injectable formulations and delivery devices and highlights the challenges pharma and its CDMO partners are facing bringing emerging parenteral breakthroughs to patients.

SPECIAL FEATURE - Injection Devices: Three Trends Influencing Development & Delivery September 1, 2022

Contributor Cindy H. Dubin showcases in this annual feature how various innovative device manufacturers are addressing the current trends in their injection designs.

SPECIAL ROUNDTABLE - Which Trends Will Have the Most Impact on Drug Development in 2022? June 6, 2022

Drug Development & Delivery posed this question to life science leaders during a recent roundtable discussion. While their responses are varied, a common theme is that COVID-19 has left a lasting impact on the industry….

SPECIAL FEATURE - Analytical Testing Trends in 2022 January 17, 2022

Contributor Cindy H. Dubin reports on the innovative technologies and techniques that several leading outsourcing providers currently offer for both small and large molecules.

Pharmapack Report Predicts Diversification of Innovation Leading to a Rise in Licensing & Partnering January 25, 2019

Pharmapack Europe (February 6-7, Paris Expo Porte de Versailles, Paris) has released a European Drug Delivery and Packaging report, ahead of the event’s opening, which highlights, major challenges and opportunities for the industry in the year ahead.

SPECIAL FEATURE - Prefilled Syringes & Parenteral Manufacturing: A Rise in Biologics & Improved Technology Give Pharma Reasons to Consider Parenteral Delivery May 2, 2017

Contributor Cindy H. Dubin speaks with some of the leading companies in this market to find out about key trends, packaging advancements, safety improvements, and technology developments.

ADVANCED DELIVERY DEVICES - How Data Hubs & Smart Devices Are Enabling the Rise of Therapeutic Ecosystems January 8, 2016

Stephen Allan discusses how unique collaborations between tech and biotech reflect a new paradigm in how therapeutics are being commercialized and marketed under the new pay-for-performance healthcare model.

A Rise in IPOs Revive Investments for Global Pharma & Biotech Industry June 3, 2014

A Rise in IPOs Revive Investments for Global Pharma & Biotech Industry May 29, 2014

Enterprise Content Management; Answer to Clinical Data Boom April 22, 2014

SPECIAL FEATURE - Outsourcing Formulation Development & Manufacturing: Early-Stage Partnerships Are On The Rise April 2, 2014

Contributor Cindy H. Dubin asked leading CMOs and CDMOs to describe the value-added services they offer with respect to formulation and manufacturing. Solving challenges of insufficient solubility, poor stability, identifying excipient candidates, and particle design topped their list of offerings.

EXECUTIVE INTERVIEW - Samsung Biologics: Exploring The Evolving Biopharma Landscape January 26, 2024

Kevin Sharp, Senior VP & Head of Sales for Samsung Biologics, discusses the evolving biopharma space, exploring current challenges, and the demand for sustainable solutions.

CARBOMER CHEMISTRY - Breaking Ground in Controlled Release December 4, 2023

Nicholas DiFranco, MEM, believes by working alone or alongside other well-established excipients for controlled release such as HPMC, the power of carbomer chemistry can help drug developers to overcome common challenges associated with controlled-release formulations without resorting to more complex techniques.

In the Global Market for Self-Injected Therapies, Vetter Sees Both Opportunities & Challenges October 30, 2023

In just the last few years, the shift toward at-home, self-administered care has become one of the defining trends in the global market for injectable therapies…..

CELL & GENE THERAPY - Cell & Gene Therapy’s Everest – The Challenges & Opportunities That Will Shape Success September 5, 2023

Samir Acharya, PhD, Rajiv Vaidya, PhD, Laura Kerepesi, PhD, and Cyrill Kellerhals, MBA, provide their unique insights as they explore the challenges cell and gene therapy developers and manufacturers are currently facing, those they can expect to see in the future, and more critically, how to overcome them.

SPECIAL FEATURE - Injection Devices: Designing in Sustainability, Usability & Digitization for Patient Compliance September 5, 2023

Contributor Cindy H. Dubin, in this exclusive annual feature, highlights how leading device and drug companies are working to address the challenges of usability, sustainability, and technology to increase patient compliance.

PLATFORM DEVICE - Alina: Shining the “Light” on the Benefits of a Platform Approach to Treating Chronic Conditions June 5, 2023

Adam Stops, PhD, says the key to the success of any drug delivery device are factors such as proven technology, low development costs, fast time-to-market, and a strong intellectual property (IP) position for the pharma company, and against this background, platform drug delivery devices have become more important than ever.